Articles tagged with Recombinant Proteins
A new vaccine platform developed at the University at Buffalo has demonstrated complete protection in mice against a deadly variant of bird flu. The vaccine, which combines key proteins hemagglutinin and neuraminidase, shows promise as a versatile and easy-to-produce vaccine that could be effective against evolving bird flu strains.
Researchers at the University of Washington have developed new proteins that can neutralize lethal snake venom toxins using deep learning computational methods. These protein designs show promise for creating safer and more cost-effective antivenoms, potentially saving millions of lives annually.
A new proteomics method, peptide-centric local stability assay (PELSA), enables the simultaneous identification of ligand-binding proteins and their binding sites in complex systems. PELSA has been shown to have superior sensitivity in target protein identifications, identifying more kinase targets than state-of-the-art methods.
The new biosensor detects symmetric dimethylarginine in urine, providing a more accurate indicator of kidney health than creatinine. It can identify mild kidney impairment and offers a reliable alternative to blood tests, enabling timely interventions and potential long-term outcomes.
Researchers developed a new system to produce high-yield proteins in lettuce by silencing specific genes. This method increases recombinant protein expression by over two times, making it a promising alternative for large-scale production.
Tobacco plant molecular farming offers advantages over traditional approaches, including lower costs and high-yield production. A comprehensive study addresses the challenge of subcellular localization for recombinant protein production, focusing on ER, vacuole, chloroplast, and apoplast targeting strategies.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers developed a new recombinant flu vaccine called Hexaplex, which provided superior protection against H1N1 and H3N2 viruses in animal models. The vaccine's combination of six proteins from different groups resulted in strong antibody production and T-cell activation, offering broader immunity.
Researchers at Brookhaven National Laboratory successfully produced large quantities of human ACE2 receptor protein in mouse cells, allowing for the study of viral receptors and potentially developing new therapies. The method could also facilitate the production of other complex proteins that have proven difficult to produce.
Researchers have developed nanodrones that target and eliminate cancer cells by recruiting natural killer cells to tumor sites. The study offers a potential solution for intractable types of cancers, with promising results in suppressing tumor growth without causing side effects.
Researchers discovered two new psychrophilic species of bacteria with cold-adapted enzymes, which can be used in biotechnology to produce refrigerated foods, improve detergent quality, and remove pollutants from cold environments. The study was conducted in collaboration with Uruguayan scientists and supported by FAPESP.
Scientists have created a method to produce synthetic spider silk with eightfold higher yields than previous methods, making it a promising material for sustainable clothing production. The new silk fibers retain the desirable properties of enhanced strength and toughness while being lightweight.
Researchers at Kyoto University have discovered a genetic mutation that causes lethal arrhythmia in humans. The study found that a novel variant of the CALM2 gene produces robust arrhythmogenicity in human-induced pluripotent stem cell-derived cardiomyocytes.
The study aims to assess the effectiveness of recombinant Factor VIIa (rFVIIa) in decreasing bleeding in the brain of patients with intracerebral hemorrhage (ICH). ICH is a deadly stroke type with no effective treatment, and this trial seeks to improve outcomes.
A new preclinical study discovered the underlying cause of gender differences in immunotherapy-associated myocarditis and identified potential treatment strategies. Hormone therapies targeting the endocrine-cardiac-immune pathway may reduce this risk without affecting treatment efficacy.
Researchers developed a novel nanobody-based detection method for recombinant human interferon α2b (rhIFNα2b), which has a lower detection limit than existing methods. The assay's operation time was shortened from two days to a few minutes, making it suitable for rapid market counterfeit detection and early diagnosis of hepatitis.
Scientists successfully produced SARS-CoV-2 protein fragments linked to bacterial flagellin in plants, enabling high-yield production and scalable vaccine development. This novel approach could make vaccines cheaper and more convenient.
Researchers in Brazil and Belgium developed a stable, immune-resistant molecule from rattlesnake venom using PEGylation. The resulting drug candidate modulates blood clotting and has potential for anti-coagulant and wound dressing applications.
Researchers have developed novel immune checkpoint proteins that can combat autoimmune diseases and immunosuppression in cancer patients. These proteins, which include recombinant proteins and antibodies, show promise in animal models of autoimmune disease and inhibit tumor growth in cancer patients.
Researchers at Seoul National University developed a synthetic protein quality control system in bacteria to increase the efficiency of protein production. This technology enhances full-length translation, leading to up to 250% increase in protein yield and over two-fold increase in target metabolite production levels.
Researchers at Far Eastern Federal University developed a technology to synthesize protein from amaranth grains and mushroom mycelium, enriching stock-raising feed. The new feed is biologically equivalent to the storage protein A1 isolated from amaranth, meeting the natural amino acid composition.
Researchers have successfully produced mammalian cell lines that can produce human glycosylation profiles for Alpha-1-antitrypsin proteins. This breakthrough enables the production of recombinant Alpha-1-antitrypsin without dependency on human donors, reducing treatment costs and improving patient outcomes.
Researchers at Lobachevsky University developed a new method for producing medical therapeutic proteins by eliminating SlyD/SlyX genes in E. coli strains, reducing contamination and increasing purification efficiency. The approach enables the production of a wide range of prokaryotic and eukaryotic proteins in a pure form.
Researchers develop a novel method for folding and protecting recombinant proteins using a protein-in-a-protein technology. This innovation improves functional protein yields and protects against various denaturants, offering potential applications in the biologics and pharmaceutical industries.
Researchers at Case Western Reserve University discovered that recombinant human prion protein inhibits the propagation of prions, which cause fatal brain diseases. The study's findings have significant implications for treating prion diseases, including Creutzfeldt–Jakob disease and mad cow disease.
Researchers have developed an immune therapy technique that can suppress fertility hormones in females and males, potentially preventing pregnancy. The treatment could be used on dogs, cats, and other mammals, as well as humans with hormonal imbalances or conditions such as androgen excess syndromes.
Researchers have successfully produced native-like spider silk in a metabolically engineered bacterium, opening up new avenues for sustainable materials and biomedical applications. The artificial fiber exhibits comparable mechanical properties to native spider silk, with high strength, extensibility, and stiffness.
The RECAN project developed novel fluorochrome dyes bound to monoclonal antibodies, enabling improved diagnosis of leukaemia and rheumatic diseases. The project also produced recombinant proteins for immunisation and created a range of specific monoclonal and polyclonal antibodies with great commercial potential.
Researchers from the Broad Institute of MIT and Harvard present a new method for identifying protein-bait interactions, allowing for sensitive detection and discrimination of specific interactions. The method uses quantitative proteomics approaches to compare enrichment with the bait of interest against samples using control baits.
Scientists have determined how a normal protein can be converted into a prion, an infectious agent causing fatal brain diseases in humans and mammals. The study provides the strongest evidence yet to prove the prion hypothesis and offers insights into molecular mechanism and potential therapeutic targets for these diseases.
A team of researchers has discovered a novel mechanism by which elastin-like polypeptides increase recombinant protein accumulation in tobacco plants. The study found that ELP fusions targeted to the endoplasmic reticulum induce the formation of mobile protein bodies, enhancing protein yield.
Scientists at Lawrence Berkeley National Laboratory create a novel technique to precisely modify recombinant proteins by introducing aldehyde tags. This breakthrough enables the labeling of therapeutic proteins in mammalian cells, paving the way for targeted treatments and improved pharmaceuticals.
Scientists develop purification process to recover recombinant gelatin from transgenic corn, addressing concerns over infectious agents and traceability. The method uses chromatographic and filtration techniques to achieve high purity, opening up new possibilities for plant-based protein production.
Transgenic tobacco plants produce recombinant proteins economically, benefiting from plant-made vaccines with reduced viral screening costs. The process of recovering and purifying these proteins is expensive, requiring development of more economical techniques to lower production costs.
A Texas Agricultural Experiment Station scientist has developed a method of producing collagen and other health-related proteins from plants, replacing human or animal sources. The process involves introducing collagen proteins into sugarcane callus, transforming the cane to produce both sugar and collagen protein in cane stems.
Baxter's rAHF/PFM therapy has shown bioequivalence with Recombinate, a current gold-standard, indicating comparable hemostatic efficacy in managing Haemophilia A. This new method reduces theoretical risk of disease transmission by eliminating human or animal-derived raw materials.
A study by Penn researchers found that a common gene delivery system for muscular dystrophy can trigger an immune response in mice unless paired with a muscle-specific promoter. The use of restricted promoters is crucial before expanding clinical trials.
Scientists at UNC Health Care have successfully used gene-therapy to produce high amounts of a clotting protein in animals, bypassing a major hurdle for treating hemophilia. The new method could potentially yield sustained factor IX production in humans, eliminating the need for daily injections.
A new study found that Staphylococcus aureus produces a toxin that breaks down the protein Desmoglein 1, causing blistering and skin cell adhesion loss. The findings provide insight into the bacterial mechanism of impetigo infection and spread.
A study published in Science demonstrates the utility of ARIAD's RAPID technology, which allows for rapid and regulated delivery of therapeutic proteins. Human insulin was successfully delivered to diabetic mice via this method, correcting blood sugar levels within minutes.
Seattle researchers have described the structure of factor VIII, a key blood-clotting protein implicated in hemophilia A. The discovery provides a key to developing improved blood-thinning medications and clotting agents for hemophiliacs, as well as better treatments for those at risk of stroke and heart attack.
Researchers have developed a new membrane-based system that can separate proteins from impurities in a single step, potentially reducing production costs and increasing efficiency. The technology, known as the 'salt cloud' concept, exploits the natural charge on proteins to improve separation rates.
Researchers are working to create a better lung surfactant mixture that can be easily produced without batch variance, tailored to specific cases. The new formulation aims to reduce mortality rates by 30-50% for infants with neonatal respiratory distress syndrome.
The Wistar Institute's Recombinant Protein and Structure Evaluation Center has been admitted to the Ben Franklin Technology PArtners' Center of Excellence Network Program for the second consecutive year. The center provides services to small and medium-sized biotechnology and pharmaceutical companies, specializing in baculovirus expres...
Researchers identify nephrin's role in the kidney's filtration barrier, finding a 'zipper-like' structure that allows blood to pass but not plasma proteins. Increasing nephrin production or restoring its function is thought to improve kidney function and restore proteinuria.
Scientists created a recombinant protein that fused heat shock proteins with ovalbumin, leading to immune response against ovalbumin-producing cancer cells. The technology could be used to develop vaccine candidates against infectious diseases like AIDS and stimulate CTL responses against cancer.
Researchers have discovered a way to harness valuable proteins from nearly dead insect pests, producing high-quality pharmaceuticals in a more cost-effective manner. The HeRD system enables the mass production of these proteins, paving the way for the development of novel vaccine treatments and alternative pesticides.
Researchers have discovered a novel physiological role for UG in mice, suggesting its essentiality in preventing kidney fibrosis and neonatal BPD. UG deficiency leads to inflammation and fibrosis of lung tissue, resulting in respiratory inhibition.